This year, the members of the association met in Bologna, Italy, for their annual general assembly. At this meeting, Klaus-Peter Behr, Chairman of EMAV, pointed out that during the reporting period, EMAV was confronted with a number of new challenges regarding the manufacturing and future availability of autogenous vaccines, which EMAV was able to successfully overcome thanks to consistently focused work, a proven and dedicated team and the use of an established network.
As scheduled, competent representatives of EMAV member companies were appointed to the extended board of the association at the meeting in Bologna. Newly elected to the board were Benedikt Üffing, Vaxxinova/DE, Aurelie Balard, Ceva-Biovac/FR and Klaus Teich, SAN Group/DE, as well as re-elected Astrid Weiss, AGES/AT, and Javier Sanz Martin, Syva/ES. In addition to these newly elected board members, Klaus-Peter Behr, Chairman/DE and Maarten de Gussem, Deputy Chair and Poulpharm/BE complete the board.
EMAV Managing Director Gerfried Zeller welcomed the election of the new board members and expressed his conviction that the involvement of these experienced experts in the field of autogenous vaccines is of particularly great importance, especially for the anticipated key decisions in the coming months regarding the legal framework for the manufacturing of these vaccines in future.